Page last updated: 2024-12-11

nitrocefin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nitrocefin: chromogenic cephalosporin used for detection of beta-lactamase activity; Cefinase is name for nitrocefin on paper disc; RN given refers to (6R-(3(E),6 alpha,7 beta))-isomer; structure for mono-Na salt in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436140
CHEMBL ID480517
SCHEMBL ID132936
MeSH IDM0076983

Synonyms (22)

Synonym
nitrocefin
(7r)-3-((e)-2,4-dinitrostyryl)-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid
CHEMBL480517
(6r,7r)-3-[(e)-2-(2,4-dinitrophenyl)ethenyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
unii-ewp54g0j8f
41906-86-9
nitrocefin [ban]
(6r-(3(e),6alpha,7beta))-3-(2-(2,4-dinitrophenyl)ethenyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
ewp54g0j8f ,
nitrocefin [mi]
SCHEMBL132936
(6r,7r)-7-[[(e)-4-(2,4-dinitrophenyl)-2-(2-thienyl)but-3-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DB11592
BCP20283
EX-A7930
Q1993962
DTXSID401318525
AS-76556
bdbm50557068
HY-108913
CS-0031509
AKOS040744420

Research Excerpts

Overview

Nitrocefin is a highly activated, chromogenic cephalosporin derivative that exhibits steady-state solvent kinetic isotope effects of 1.4 on both V and V/K. It is a key reagent for high and low throughput assays of the activities of penicillin-binding proteins (PBPs) and beta-lactamases.

ExcerptReferenceRelevance
"Nitrocefin is a highly activated, chromogenic cephalosporin derivative that exhibits steady-state solvent kinetic isotope effects of 1.4 on both V and V/K."( Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by β-lactamase from Mycobacterium tuberculosis.
Blanchard, JS; Chow, C; Xu, H, 2013
)
1.38
"Nitrocefin is a key reagent for high and low throughput assays of the activities of penicillin-binding proteins (PBPs) and beta-lactamases, the former used for discovery of antibiotics and the latter for inhibitors of resistance determinants for beta-lactam antibiotics. "( A practical synthesis of nitrocefin.
Hesek, D; Lee, M; Mobashery, S, 2005
)
2.07

Compound-Compound Interactions

ExcerptReferenceRelevance
" Rifampicin combined with kaempferol or quercetin exhibited good beta-lactamase inhibitory effects (57."( The effects of antibiotics combined with natural polyphenols against clinical methicillin-resistant Staphylococcus aureus (MRSA).
Chin, YP; Hou, WC; Lee, MH; Lin, RD, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (22)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)IC50 (µMol)100.00001.60001.60001.6000AID1707626
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Citrobacter freundiiKm32.00005.00007.00009.0000AID405084
Metallo-beta-lactamase VIM-11 Pseudomonas aeruginosaKm8.20004.50007.00009.4000AID520385
Metallo-beta-lactamase VIM-2Pseudomonas aeruginosaKm13.80005.50007.87509.9000AID520386
Beta-lactamaseEnterobacter cloacaeKm56.00002.90006.43649.8000AID368498
Beta-lactamase OXA-10Pseudomonas aeruginosaKm20.00007.90007.90007.9000AID420527
Beta-lactamaseSerratia marcescensKm14.00002.10002.10002.1000AID368725
Beta-lactamasePseudomonas aeruginosa PAO1Km21.50000.50004.24448.0000AID368539; AID495692
Beta-lactamaseMorganella morganiiKm31.00007.90007.90007.9000AID368531
B2 metallo-beta-lactamase Chryseobacterium indologenesKm43.00003.00003.00003.0000AID562337
Efflux transporter Salmonella enterica subsp. enterica serovar NewportKm10.00000.10003.875010.0000AID540966
Beta-lactamase Klebsiella pneumoniaeKm7.30000.10003.02507.3000AID540967
Beta-lactamase Escherichia coliKm40.00000.00461.41494.5000AID495691
Metallo-beta-lactamaseEscherichia coliKm18.00002.00006.857110.0000AID583094
Beta-lactamase Klebsiella pneumoniaeKm120.00001.00004.45007.9000AID1320835; AID1320837
Beta-lactamase VIM-4 Pseudomonas aeruginosaKm10.000010.000010.000010.0000AID420529
Carbapenem-hydrolyzing beta-lactamase KPCKlebsiella pneumoniaeKm6.00001.60003.80006.0000AID548044
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaKm18.00002.00006.65009.4000AID531315
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
retinoid metabolic processN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
temperature homeostasisN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
phospholipid catabolic processN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
host-mediated regulation of intestinal microbiota compositionN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
positive regulation of inflammatory responseN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
N-acylphosphatidylethanolamine metabolic processN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
positive regulation of brown fat cell differentiationN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
N-acylethanolamine metabolic processN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
zinc ion bindingN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
bile acid bindingN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
identical protein bindingN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
N-acylphosphatidylethanolamine-specific phospholipase D activityN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
Golgi membraneN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
nuclear envelopeN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
nucleoplasmN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
early endosomeN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
Golgi apparatusN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
early endosome membraneN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
photoreceptor outer segment membraneN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
extracellular exosomeN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
membrane-bounded organelleN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
cytoplasmN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (132)

Assay IDTitleYearJournalArticle
AID583090Activity of Escherichia coli XL1-Blue IMP-1 W64A mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID520385Activity at Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11 by spectrometry2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID583092Activity of Escherichia coli XL1-Blue VIM-2 A64W mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID1320838Activity of native signal deficient and TEV cleavage site containing His-tagged Klebsiella pneumoniae OXA-48 expressed in Escherichia coli assessed as ratio of Kcat to Km by Michaelis-Menten kinetics assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID368531Activity of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID340736Activity of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID727655Activity of Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID1320835Activity of native signal containing Klebsiella pneumoniae OXA-48 by Michaelis-Menten kinetics assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID583087Ratio of Kcat to Km for Escherichia coli XL1-Blue VIM-2 A64W mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID540966Activity of Salmonella enterica serotype Newport AM17274 cephalosporinase CMY-31 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID420529Activity of Pseudomonas aeruginosa VIM4 beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID531760Activity of beta-lactamase AmpC in Pseudomonas aeruginosa EryR by spectrophotometry2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID368727Ratio of Kcat to Km of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID548259Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant by spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID727656Activity of wild type Beta-lactamase SHV-1 in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID587733Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID548260Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant by spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID420531Ratio of Kcat to Km for Enterobacter cloacae NMCA beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID766242Activity at recombinant IMP-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID340737Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID587732Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID766240Activity at recombinant NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID531316Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID519012Activity of Beta-lactamase TEM-102008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID368532Activity of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID766250Inhibition of recombinant SPM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells by fluorescence-based assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID545145Ratio of Kcat to Km of CMY-2 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID520388Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-22008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID495691Activity of Escherichia coli CMY-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531762Activity of beta-lactamase AmpC in Pseudomonas aeruginosa 2439 by spectrophotometry2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID766243Activity at recombinant SPM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID496594Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase KPC-22010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID562326Activity of Aeromonas hydrophila metallo-betalactamase CphA N233A mutant expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site.
AID531759Activity of beta-lactamase AmpC in Pseudomonas aeruginosa PAO1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID420525Activity of TEM1 beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID496593Activity at Escherichia coli DH10B beta-lactamase KPC-2 by diode array spectrophotometry2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID519010Activity of Beta-lactamase TEM-149 T182M mutant expressed in Escherichia coli HB1012008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID766249Ratio of Kcat to Km for recombinant Bc2 (unknown origin)2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID519008Activity of Beta-lactamase TEM-149 expressed in Escherichia coli HB1012008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID519009Ratio of Kcat to Km for Beta-lactamase TEM-149 expressed in Escherichia coli HB1012008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID560703Ratio of Kcat to Km for Escherichia coli MC4100 Beta-Lactamase CMY-22009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID531317Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID583091Activity of Escherichia coli XL1-Blue wild-type IMP-1 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID548264Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237E mutant by spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID495706Kcat/Km ratio of Escherichia coli CMY-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531763Activity of beta-lactamase AmpC in Pseudomonas aeruginosa 2126 by spectrophotometry2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID368725Activity of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID531313Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID560704Selectivity ratio of Kcat for Escherichia coli MC4100 Beta-Lactamase CMY-2 to Kcat for Escherichia coli MC4100 Beta-Lactamase CMY-30 Val211?Gly211 mutant2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID420533Ratio of Kcat to Km for Bacillus cereus BC2 beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID543431Activity at Shigella sonnei UIH-1 beta-lactamase CTX-M-64 by spectrophotometry2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID548265Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237E mutant by spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID766246Ratio of Kcat to Km for recombinant VIM-2 (unknown origin)2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID368498Activity of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID405085Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID438298Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID766248Ratio of Kcat to Km for recombinant SPM-1 (unknown origin)2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID1320836Activity of native signal containing Klebsiella pneumoniae OXA-48 assessed as ratio of Kcat to Km by Michaelis-Menten kinetics assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID368533Ratio of Kcat to Km of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1707626Inhibition of full length human NAPE-PLD expressed in HEK293T cell lysate using PED6 as substrate preincubated for 30 mins followed by substrate addition and measured at 2 mins interval for 1 hr by tecan-plate reader analysis2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Structure-Activity Relationship Studies of Pyrimidine-4-Carboxamides as Inhibitors of
AID495737Kcat/Km ratio of Pseudomonas aeruginosa AmpC relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID540967Activity of Klebsiella pneumoniae HP205 cephalosporinase CMY-36 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID495692Activity of Pseudomonas aeruginosa AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID766244Activity at recombinant Bc2 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID340738Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID420527Activity of Pseudomonas aeruginosa OXA10 beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID368540Activity of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368522Ratio of Kcat to Km of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry relative to cephaloridine2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID727654Ratio of Kcat to Km for wild type Beta-lactamase SHV-1 in Escherichia coli DH10B2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID368541Ratio of Kcat to Km of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID562337Activity at Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID511291Activity of Pseudomonas aeruginosa GES-13 beta lactamase assessed as hydrolysis by spectrometry2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID420534Ratio of Kcat to Km for Pseudomonas aeruginosa VIM4 beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID766245Ratio of Kcat to Km for recombinant NDM-1 (unknown origin)2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID560701Ratio of Kcat to Km for Escherichia coli MC4100 Beta-Lactamase CMY-30 harboring Val211?Gly211 mutation2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID1320837Activity of native signal deficient and TEV cleavage site containing His-tagged Klebsiella pneumoniae OXA-48 expressed in Escherichia coli by Michaelis-Menten kinetics assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID368728Ratio of Kcat to Km of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368542Ratio of Kcat to Km of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID531761Activity of beta-lactamase AmpC in Pseudomonas aeruginosa 3308 by spectrophotometry2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID543433Ratio of Kcat to km for Shigella sonnei UIH-1 CTX-M-642009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID548044Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID548263Selectivity index, Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant to ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID520386Activity at Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 by spectrometry2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID495721Activity of Escherichia coli CMY-2 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID766247Ratio of Kcat to Km for recombinant IMP-1 (unknown origin)2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID420526Activity of Enterobacter cloacae NMCA beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID420528Activity of Bacillus cereus BC2 beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID766241Activity at recombinant VIM-2 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID587730Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID368520Activity of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry relative to cephaloridine2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID548261Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant by spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID548258Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID583088Ratio of Kcat to Km for Escherichia coli XL1-Blue wild-type IMP-1 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID727653Ratio of Kcat to Km for Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID368539Activity of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID520387Ratio of Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-112008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID583094Activity of Escherichia coli XL1-Blue wild-type VIM-2 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID583089Ratio of Kcat to Km for Escherichia coli XL1-Blue wild-type VIM-2 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID562324Activity of Aeromonas hydrophila metallo-betalactamase CphA expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site.
AID368534Ratio of Kcat to Km of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID562325Ratio of Kcat to Km for Aeromonas hydrophila metallo-betalactamase CphA expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site.
AID562341Ratio of Kcat to Km for Chryseobacterium meningosepticum CCUG 4310 beta-lactamase BlaB1 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID420530Ratio of Kcat to Km for TEM1 beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID420532Ratio of Kcat to Km for Pseudomonas aeruginosa OXA10 beta-lactamase2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID511292Ratio of Kcat/Km for Pseudomonas aeruginosa GES-13 beta lactamase assessed as hydrolysis by spectrometry2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID405084Activity of Citrobacter freundii PER2 beta lactamase2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID519011Ratio of Kcat to Km for Beta-lactamase TEM-149 T182M mutant expressed in Escherichia coli HB1012008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID368726Activity of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368521Ratio of Kcat to Km of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID495736Kcat/Km ratio of Escherichia coli CMY-2 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID525581Activity of Beta-lactamase OXA-1 expressed in Escherichia coli BL21 (DE3)2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Penicillin sulfone inhibitors of class D beta-lactamases.
AID525582Ratio of Kcat to Km for Beta-lactamase OXA-1 expressed in Escherichia coli BL21 (DE3)2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Penicillin sulfone inhibitors of class D beta-lactamases.
AID560702Activity of Escherichia coli MC4100 Beta-Lactamase CMY-22009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID560497Activity of Escherichia coli MC4100 Beta-Lactamase CMY-30 harboring Val211?Gly211 mutation2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID531764Activity of beta-lactamase AmpC in Pseudomonas aeruginosa 1956 by spectrophotometry2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID531314Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID531315Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID519013Ratio of Kcat to Km for Beta-lactamase TEM-102008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID495707Kcat/Km ratio of Pseudomonas aeruginosa AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID587731Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID545143Ratio of Kcat to Km for Klebsiella pneumoniae cephalosporinase CMY-36 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID438297Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID545144Activity of CMY-2 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID520389Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 over Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-112008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID531318Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID548262Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant by spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID562327Ratio of Kcat to Km for Aeromonas hydrophila metallo-betalactamase CphA N233A mutant expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site.
AID540968Ratio of Kcat to Km for Salmonella enterica serotype Newport AM17274 cephalosporinase CMY-31 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID405086Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase relative to cephalothin2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID583086Ratio of Kcat to Km for Escherichia coli XL1-Blue IMP-1 W64A mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID562338Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID495722Activity of Pseudomonas aeruginosa AmpC relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (201)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (14.43)18.7374
1990's34 (16.92)18.2507
2000's71 (35.32)29.6817
2010's58 (28.86)24.3611
2020's9 (4.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.62 (24.57)
Research Supply Index5.32 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index64.36 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other203 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]